Please ensure Javascript is enabled for purposes of website accessibility

GlaxoSmithKline Plans to Produce 1 Billion Doses of Its Pandemic Vaccine Adjuvant in 2021

By Brian Orelli, PhD – Updated May 28, 2020 at 2:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Simply put, adjuvants make vaccines work better; this one could be useful in conjunction with a number of SARS-CoV-2 vaccine candidates.

GlaxoSmithKline (GSK 0.24%) is ramping up production of its pandemic adjuvant, an additive that boosts the effectiveness of  vaccines. The U.K.-based drugmaker expects to be able to produce 1 billion doses of the adjuvant in 2021 for use with an array of SARS-CoV-2 vaccines.

This same adjuvant was used in the last flu pandemic, and, in theory, it should work with a variety of protein-based vaccines. Of course, we'll have to wait for clinical trial data to know for sure that it has the desired effect when used with vaccines for SARS-CoV-2, which causes COVID-19.

When used in conjunction with weaker vaccines, an adjuvant can increase the immune response, producing stronger and longer-lasting immunity. For vaccines that are sufficiently effective on their own, an adjuvant can reduce the amount of vaccine protein required per dose. In a pandemic, that can be a huge benefit, allowing significantly more people to be protected by a relatively limited supply of vaccine while manufacturers work to ramp up their production.

Hands giving an injection into a shoulder

Image source: Getty Images.

GlaxoSmithKline has partnerships with several companies that are developing SARS-CoV-2 vaccine candidates and is in ongoing discussions with potential additional collaborators.

The company has already started manufacturing the adjuvant in quantity even though so far, no protein-based COVID-19 vaccines in development have reached the stage where they've produced human clinical trial data. A phase 1 study of Moderna's (MRNA 0.15%) mRNA-1273 COVID-19 vaccine has produced data, but that's an mRNA-based vaccine, not protein-based, so GlaxoSmithKline's adjuvant likely wouldn't be a useful additive to it.

Going to heavy production now could cost GlaxoSmithKline some money if it turns out its adjuvant isn't helpful with any of the vaccines that it's tested in, or if the vaccines that prove most effective (and are therefore widely used) are not protein-based.

Still, the decision to ramp up production seems like a reasonable risk to take, given its previous success with the 2017-2018 pandemic flu vaccine and considering the unprecedented need for effective responses to COVID-19. The company is also talking with governments and global institutions about the possibility that they might help fund its production of the adjuvant.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GSK Stock Quote
GSK
GSK
$29.43 (0.24%) $0.07
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$118.25 (0.15%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.